Harvard Bioscience (FRA:HBI) Additional Paid-In Capital : €214.78 Mil(As of Mar. 2024)

View and export this data going back to . Start your Free Trial

What is Harvard Bioscience Additional Paid-In Capital?

Harvard Bioscience's quarterly additional paid-in capital declined from Sep. 2023 (€218.22 Mil) to Dec. 2023 (€213.14 Mil) but then increased from Dec. 2023 (€213.14 Mil) to Mar. 2024 (€214.78 Mil).

Harvard Bioscience's annual additional paid-in capital increased from Dec. 2021 (€199.70 Mil) to Dec. 2022 (€216.18 Mil) but then declined from Dec. 2022 (€216.18 Mil) to Dec. 2023 (€213.14 Mil).

Harvard Bioscience Additional Paid-In Capital Historical Data

The historical data trend for Harvard Bioscience's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Harvard Bioscience Additional Paid-In Capital Chart

Harvard Bioscience Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

206.27

191.00

199.70

216.18

213.14

Harvard Bioscience Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Additional Paid-In Capital	Get a 7-Day Free Trial															214.92	213.71	218.22	213.14	214.78

Harvard Bioscience Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Harvard Bioscience Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Harvard Bioscience's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Harvard Bioscience (FRA:HBI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Harvard Bioscience Inc (FRA:HBI) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

HBIO:USA HBI:Germany

Address

84 October Hill Road, Holliston, MA, USA, 01746

Website

https://www.harvardbioscience.com

Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, specialized products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. Its primary focus is scientific instruments used to advance life science and research. With operations in North America, Europe and china it sells through a combination of direct and distribution channels to customers around the world. The product brands of the company include Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab.. The majority of its revenue comes from the United States.